How do you decide between enrolling an oligometastatic NSCLC patient on LU-002 versus treating them with SBRT off trial?  

Since the randomized phase II data from Gomez et al presented at ASTRO 2018 showed a survival benefit, is there concern about randomizing patients to a study that has an arm with documented worse survival?

Answer from: Radiation Oncologist at Academic Institution